WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018081367) CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/081367    International Application No.:    PCT/US2017/058451
Publication Date: 03.05.2018 International Filing Date: 26.10.2017
IPC:
A61K 38/12 (2006.01), A61K 38/22 (2006.01), A61K 38/17 (2006.01), C07K 14/575 (2006.01), C07K 14/46 (2006.01)
Applicants: JANSSEN PHARMACEUTICA NV [BE/BE]; Turnhoutseweg 30 B-2340 Beerse (BE).
MACIELAG, Mark [US/US]; (US)
Inventors: MACIELAG, Mark; (US).
MACIELAG, Mark; (US).
PATCH, Raymond, J.; (US).
ZHANG, Rui; (US).
CASE, Martin A.; (US).
WALL, Mark; (US).
ZHANG, Yue-Mei; (US)
Agent: BARANIAK, Andrew, P.; (US)
Priority Data:
62/413,586 27.10.2016 US
62/413,613 27.10.2016 US
Title (EN) CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS
(FR) COMPOSÉS PEPTIDIQUES CYCLIQUES TYROSINE-TYROSINE À TITRE DE MODULATEURS DES RÉCEPTEURS DU NEUROPEPTIDE Y
Abstract: front page image
(EN)The present invention comprises compounds of Formula I wherein: Z4, Z7, Z9, Z11, Z22, Z23, Z26, Z30, Z34, Z35, p, m, n, q, and BRIDGE are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel compounds are useful for preventing, treating or ameliorating diseases and disorders, such as obesity, type 2 diabetes, the metabolic syndrome, insulin resistance, and dyslipidemia, among others.
(FR)La présente invention comprend des composés de formule I où : Z4, Z7, Z9, Z11, Z22, Z23, Z26, Z30, Z34, Z35, p, m, n, q, et PONT sont tels que définis dans la description. Des compositions pharmaceutiques et leurs méthodes d'utilisation sont en outre décrites. Les nouveaux composés sont utiles pour prévenir, traiter ou améliorer des maladies et des troubles, tels que l'obésité, le diabète de type 2, le syndrome métabolique, la résistance à l'insuline, et la dyslipidémie, entre autres.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)